Naoki Hiramatsu

Naoki Hiramatsu

Auto-generated profile, based on publicly available information

Naoki Hiramatsu

Department of Gastroenterology and Hepatology, Osaka Rosai Hospital, 1179-3 Nagasonecho, Kita Ward, Sakai 591-8025, Osaka, Japan

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
TOTsugiko Oze
Tsugiko Oze
NHNaoki Hiramatsu
Naoki Hiramatsu
TYTakayuki Yakushijin
Takayuki Yakushijin
MMMasanori Miyazaki
Masanori Miyazaki
AYAkira Yamada
Akira Yamada
TTTetsuo Takehara
Tetsuo Takehara

10 December 2018 in Nutrients
Verified
Journal Article
Open access
PDF file
AHAtsushi Hosui
Atsushi Hosui
EKEiji Kimura
Eiji Kimura
SASumiko Abe
Sumiko Abe
TTTakashi Tanimoto
Takashi Tanimoto
KOKohsaku Ohnishi
Kohsaku Ohnishi
NHNaoki Hiramatsu
Naoki Hiramatsu
Zinc plays a pivotal role in various zinc enzymes, which are crucial in the maintenance of liver function. Patients with chronic liver diseases (CLDs) usually have lower concentrations of zinc, which decrease further as liver fibrosis progresses. Whether long-term zinc supplementation improves liver function and reduces the risk of hepatocellular carcinoma (HCC) development remains unknown. Two hundred and sixty-seven patients with CLDs who received a zinc preparation (Zn-group; 196 patients), or who did not receive zinc (no Zn-treatment group; 71 patients), were retrospectively analyzed in this study. The Zn-group was divided into 4 groups according to their serum Zn concentrations at 6 months after the start of Zn treatment. Liver function significantly deteriorated in the no Zn-treatment group, while no notable change was observed in the Zn-group. The cumulative incidence rates of events and HCC at 3 years were observed to be lower in the Zn-group (9.5%, 7.6%) than in the no Zn-treatment group (24.9%, 19.2%) (p < 0.001). According to serum Zn concentrations, the cumulative incidence rates of events and HCC were significantly decreased in patients with Zn concentrations ≥ 70 µg/dL (p < 0.001). Zinc supplementation appears to be effective at maintaining liver function and suppressing events and HCC development, especially among patients whose Zn concentration is greater than 70 µg/dL.

14 October 2014 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
NHNaoki Hiramatsu
Naoki Hiramatsu
TOTsugiko Oze
Tsugiko Oze
TTTetsuo Takehara
Tetsuo Takehara

29 July 2009 in Journal of Viral Hepatitis
Verified
Journal Article
Closed access
PDF file
NHN. Hiramatsu
N. Hiramatsu
TOT. Oze
T. Oze
TYT. Yakushijin
T. Yakushijin
YIY. Inoue
Y. Inoue
TIT. Igura
T. Igura
NHN. Hayashi
N. Hayashi

11 January 2012 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MKMika Kurokawa
Mika Kurokawa
NHNaoki Hiramatsu
Naoki Hiramatsu
TOTsugiko Oze
Tsugiko Oze
TYTakayuki Yakushijin
Takayuki Yakushijin
MMMasanori Miyazaki
Masanori Miyazaki
TTTetsuo Takehara
Tetsuo Takehara

5 September 2013 in Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
NMNaoki Morishita
Naoki Morishita
NHNaoki Hiramatsu
Naoki Hiramatsu
TOTsugiko Oze
Tsugiko Oze
NHNaoki Harada
Naoki Harada
RYRyoko Yamada
Ryoko Yamada
TTTetsuo Takehara
Tetsuo Takehara